Dr. Redfield is currently a chief resident in the general surgery program and will be pursuing a career in abdominal transplantation. He completed a two-year transplant immunobiology research fellowship within the Harrison Department of Surgical Research at the University of Pennsylvania under the direction of Dr. Ali Naji were his research into novel plasma cell directed therapies for pre-sensitized transplant recipients was awarded the 2011 Young Investigator Award at the 2011 American Transplant Congress.  He will begin his transplant fellowship in July 2013 at the University of Wisconsin. 

• Alpha Omega Alpha
• American Medical Association (Resident Member)
• American College of Surgeons (Resident Member)
• American Society of Transplantation
• Pennsylvania Medical Society

1. Redfield RR, Parsons RF, Rodriguez E, Noorchashm H, Naji A, Abt P: Bortezomib Alone Is Sufficient To Eliminate Plasma Cells and Donor-Specific Antibody in Mice. AJT. Submitted.
2. Redfield RR, Naji A: Progression of MGUS to Multiple Myeloma in a Solid Organ Transplant. Transplantation. Accepted for Publication.
3. Redfield RR, Rodriguez E, Parsons RF, Noorchashm H, Naji A: The Essential Role of B Cells in Transplantation Tolerance. Curr Opin Immunol. Oct;23(5):685-91, 2011.
4. Redfield RR*, Parsons RF*, Rodriguez E, Naji A, Noorchashm H. Primary B Cell Repertoire Remodeling to Achieve Humoral Transplant Tolerance. Seminars in Immunology. In press 2011 *Contributed equally to publication.
5. Redfield RR, Parsons RF, Levine M, and Abt P: Underutilization of A2 Incompatible Transplants. Clinical Transplantation. In press 2011.
6. Vivek, K, Mustafa, MM, Rodriguez E, Redfield RR, Migone TS, Cancro, MP Naji A , and Noorchashm H. Strategies for B-lymphocyte repertoire remodeling in transplantation tolerance. Immunol Res. Oct;51(1):1-4, 2011.
7. Parsons RF, Vivek K, Rostami SY, Zekavat G, Ziaie SM, Luo Y, Koeberlein B, Redfield RR, Cancro MP, Naji A, Noorchashm. Acquisition of humoral transplantation tolerance upon de novo emergence of B lymphocytes. J Immunol. 186(1):614-20, 2011.
8. Parsons, RF, Vivek K, Redfield RR, Migone TS, Cancro MP, Naji A, and Noorchashm H: B Lymphocyte Homeostasis and BLyS Directed Immunotherapy in Transplantation. Transplant Rev. 24(4):207-21, 2010.
9. Parsons, RF, Vivek K, Redfield RR, Migone TS, Cancro MP, Naji A, and Noorchashm H B cell Tolerance In Transplantation: Is Repertoire Remodeling The Answer? Expert Rev Clin Immunol. 5(6):703, 2009.

1. Redfield RR, Parsons RF, Naji A, Abt P: Bortezomib Alone Is Sufficient To Cause Sustained Elimination of Allo-reactive Plasma Cells and Donor-Specific Antibody in Mice. ACS Clinical Congress, San Francisco 2011.
2. Redfield RR, Parsons RF, Luo Y, Rostami S, Vivek K, Rodriguez E, Mustafa MM, Noorchashm H, Naji A, Abt PL. Bortezomib Alone Is Sufficient To Eliminate Plasma Cells and Donor-Specific Antibody in Mice. American Transplant Congress. 2011.
3. Redfield RR, Luo Y, Rostami S, Vivek K, Rodriguez E, Mustafa MM, Noorchashm H, Naji A, Abt PL., Parsons RF, RANKL-Directed Immunotherapy Reduces Donor Specific Antibodies in Sensitized Mice. American Transplant Congress. 2011.

1. Redfield RR, Parsons RF, Luo Y, Rostami S, Vivek K, Rodriguez E, Mustafa MM, Noorchashm H, Naji A, Abt PL. Bortezomib Alone Is Sufficient To Eliminate Plasma Cells and Donor-Specific Antibody in Mice. American Transplant Congress. 2011.
2. Redfield RR, Luo Y, Rostami S, Vivek K, Rodriguez E, Mustafa MM, Noorchashm H, Naji A, Abt PL., Parsons RF, RANKL-Directed Immunotherapy Reduces Donor Specific Antibodies in Sensitized Mice. American Transplant Congress. 2011.
3. Rodriguez E, Redfield RR, Vivek K, Rodriguez E, Mustafa MM, Naji A, Noorchashm H. Dysregulated B Lymphocyte Tolerance to Self-Antigens Results from Cardiac Allograft Rejection. American Transplant Congress. 2011.
4. Vivek K, Rostami S, Mustafa M, Rodriguez E, Redfield RR, Luo Y, Ziaie S, Parsons, RF, Migone TS, Cancro MP, Naji A, Noorchashm.H. B-Lymphocyte Directed Immunotherapy at the Time of Induction Is Insufficient for the Establishment of Humoral Transplantation Tolerance. American Transplant Congress. 2011.
5. Vivek K, Rostami S, Mustafa M, Rodriguez E, Redfield RR, Luo Y, Ziaie S, Parsons, RF, Migone TS, Cancro MP, Naji A, Noorchashm.H. BLyS-Directed Immunotherapy Purges Alloreactive Specificities from the Primary B-Cell Repertoire and Promotes Humoral Transplantation Tolerance. American Transplant Congress. 2011.
6. Redfield RR, Parsons RF, Levine M, and Abt P: Outcomes of A2 Incompatible Transplants. American Transplant Congress. 2010.
7. Parsons R, Vivek, K, Redfield RR, Rostami S, Migone T, Cancro M, Naji A, Noorchashm, H: De Novo Emergence of the B-Lymphocyte Compartment in the Presence of Alloantigen Promotes a Robust State of Humoral Transplantation Tolerance. American Transplant Congress. 2010. Accepted
8. Parsons R, Yu M, Vivek K, Redfield RR, Rostami S, Zekavat G, Koeberlein B, Migone T, Cancro M, Naji A, Noorchashm H.: A Preponderance of Transitional B-Cells Following In Vivo BLyS Neutralization Promotes a Sustained State of Donor Specific Transplantation Tolerance. American Transplant Congress. 2010.
9. Parsons RF, Vivek K, Redfield RR, Naji A, and Noorchasm H, In Vivo BLyS Neutralization Induces Robust Transplantation Tolerance by down-regulating APC costimulation and polarizing T cell cytokine Profiles. AST Distinguished Fellows Research Forum. October, 2009, San Diego, California.